Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

COVID-19 Analyst Consensus Sales Report Overview

Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within the 5-year period of 2021-26, forecast sales have grown considerably, with the H2 2022 forecast being greater than Q4 2020 forecasts.

The COVID-19 analyst consensus sales market research report contains a summary of the analyst consensus forecasts available in the GlobalData pharma intelligence center drug sales and analyst consensus database for the indication COVID-19.

COVID-19 Analyst Consensus Sales Forecast by Prophylactic Vaccines

Some of the key prophylactic vaccines analyzed for COVID-19 analyst consensus sales are Comirnaty, Spikevax, Nuvaxovid, Vaxzevria, COVID-19 Vaccine, VidPrevtyn Beta, VLA-2001, Convidecia, Covaxin, and Coronavirus Disease 2019 (COVID-19) vaccine. Comirnaty continues to be the leading prophylactic vaccine by forecast sales. Both Spikevax and Comirnaty have gained approval for their bivalent vaccines.

For more insights on COVID-19 prophylactic drugs analyst consensus sales forecast, download a free report sample

COVID-19 Analyst Consensus Sales Forecast by Therapeutic Drugs

Some of the key therapeutic drugs analyzed for COVID-19 analyst consensus sales are Paxlovid, Veklury, Regen-Cov, Lagevrio, Evusheld, Bamlanivimab/Etesevimab, Xevudy, Bebtelovimab, Amubarvimab + Romlusevimab, and Regkirona. Paxlovid is currently the leading therapeutic drug by forecast sales. Paxlovid and Lagevrio are the only two approved oral antiviral COVID-19 therapeutics on the market.

For more insights on COVID-19 therapeutic drugs analyst consensus sales forecast, download a free report sample

COVID-19 Analyst Consensus Sales Forecast by Drugs

The top three marketed drugs with the highest peak forecast sales are Pfizer/BioNTech SE’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid. The top three forecast drugs are all currently marketed, suggesting that the COVID-19 market has matured and that it will be hard for new products to supplant these leading drugs. This report provides an overview of the sales forecast for 52 drugs in clinical development or marketed for COVID-19.

COVID-19 Global Analyst Consensus Sales Forecast Analysis, by Drugs

COVID-19 Global Analyst Consensus Sales Forecast Analysis, by DrugsFor more drug insights into the COVID-19 analyst consensus sales forecast, download a free report sample

COVID-19 Analyst Consensus Sales Forecast - Top Three Marketed COVID-19 Drugs

The top three marketed COVID-19 forecast drugs include two prophylactic vaccines – Comirnaty and Spikevax – and one therapeutic drug – Paxlovid. The forecast sales of both Comirnaty and Spikevax are expected to decline from 2022 onwards, despite novel bivalent vaccine formulations, due to a reduction in mass vaccination programs. The forecast sales of Spikevax are expected to peak in 2022. The sales of Comirnaty already peaked in 2021. Furthermore, the forecast sales of Paxlovid are expected to peak in 2022 due to its approval at the end of 2021.

To know more about top marketed COVID-19 drugs with peak forecast, download a free report sample

COVID-19 Analyst Consensus Sales Report Overview

 Key Prophylactic  Vaccines Comirnaty, Spikevax, Nuvaxovid, Vaxzevria, COVID-19 Vaccine, VidPrevtyn Beta, VLA-2001, Convidecia, Covaxin, and Coronavirus Disease 2019 (COVID-19) vaccine
 Key Therapeutic Drugs Paxlovid, Veklury, Regen-Cov, Lagevrio, Evusheld, Bamlanivimab/Etesevimab, Xevudy, Bebtelovimab, Amubarvimab + Romlusevimab, and Regkirona

Reasons to Buy

  • Analysis of COVID-19 analyst consensus sales forecasts
  • Detailed Analysis of how COVID-19 have affected analyst consensus sales forecasts for previously forecasted drugs
  • Detailed analysis of how COVID-19 forecasts changed from 2020 to 2022 and what drove these changes

Table of Contents

1 COVID-19 Global Analyst Consensus Sales Forecast

1.1 COVID-19 Prophylactic Vaccines with Global Analyst Consensus Sales Forecast

1.2 COVID-19 Therapeutic Drugs with Global Analyst Consensus Sales Forecast

1.3 COVID-19 Global Analyst Consensus Sales Forecast

1.4 Top Three Marketed COVID-19 Drugs with Peak Forecast: Global Analyst Consensus Sales Forecast

2 COVID-19 Prophylactic Vaccine and Therapeutic Drugs: Global Analyst Consensus Sales Forecasts

2.1 COVID-19 Prophylactic Vaccines Global Analyst Consensus Sales Forecast & Percentage Change from H1 2022 to H2 2022

2.2 COVID-19 Therapeutic Drugs Global Analyst Consensus Sales Forecast & Percentage Change from H1 2022 to H2 2022

3 COVID-19 Analyst Consensus Sales Forecast 2020 Versus 2022

3.1 COVID-19 Global Analyst Consensus Sales Forecast: Q4 2020 Versus H2 2022

3.2 Percentage Change from Q4 2020 to H2 2022 Global Analyst Consensus Sales Forecast Total COVID-19

4 BioNTech SE

4.1 Global Analyst Consensus Sales Forecast – Comirnaty

4.2 Percentage Change from H1 2022 to H2 2022 & Q4 2020 to H2 2022 Global Analyst Consensus Sales Forecast Comirnaty

5 Pfizer

5.1 Global Analyst Consensus Sales Forecast – Paxlovid

5.2 Percentage Change from H1 2022 to H2 2022 Global Analyst Consensus Sales Forecast – Paxlovid

6 Moderna

6.1 Global Analyst Consensus Sales Forecast – Spikevax

6.2 Percentage Change from H1 2022 to H2 2022 & Q4 2020 to H2 2022 Global Analyst Consensus Sales Forecast – Spikevax

7 Key Findings

8 Appendix

8.1 Methodology

8.2 Related Reports

8.3 About the Authors

8.4 About GlobalData

8.5 Contact Us

Frequently asked questions

Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022 thematic reports
Currency USD
$495

Can be used by individual purchaser only

$990

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022 in real time.

  • Access a live Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.